{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:40:15Z","timestamp":1793425215885,"version":"4.5.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,1,10]],"date-time":"2018-01-10T00:00:00Z","timestamp":1515542400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajog.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.ajog.2017.12.206","type":"journal-article","created":{"date-parts":[[2017,12,21]],"date-time":"2017-12-21T13:05:35Z","timestamp":1513861535000},"page":"563-572.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["The past, present, and future of selective progesterone receptor modulators in the management of uterine fibroids"],"prefix":"10.1016","volume":"218","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2042-3751","authenticated-orcid":false,"given":"Sukhbir S.","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liane","family":"Belland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3437-0723","authenticated-orcid":false,"given":"Nicholas","family":"Leyland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9159-3400","authenticated-orcid":false,"given":"Sarah","family":"von Riedemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ally","family":"Murji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajog.2017.12.206_bib1","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1067\/mob.2003.99","article-title":"High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence","volume":"188","author":"Baird","year":"2003","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.12.206_bib2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1701-2163(15)30338-8","article-title":"The management of uterine leiomyomas","volume":"37","author":"Vilos","year":"2015","journal-title":"J\u00a0Obstet Gynaecol Can"},{"key":"10.1016\/j.ajog.2017.12.206_bib3","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1210\/en.2009-1225","article-title":"Progesterone is essential for maintenance and growth of uterine leiomyoma","volume":"151","author":"Ishikawa","year":"2010","journal-title":"Endocrinology"},{"key":"10.1016\/j.ajog.2017.12.206_bib4","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.fertnstert.2015.04.024","article-title":"Increased progesterone receptor expression in uterine leiomyoma: correlation with age, number of leiomyomas, and clinical symptoms","volume":"104","author":"Tsigkou","year":"2015","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ajog.2017.12.206_bib5","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.fertnstert.2011.08.021","article-title":"Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety","volume":"96","author":"Bouchard","year":"2011","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ajog.2017.12.206_bib6","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/humupd\/dmw023","article-title":"Uterine fibroid management: from the present to the future","volume":"22","author":"Donnez","year":"2016","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.ajog.2017.12.206_bib7","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.mce.2012.02.021","article-title":"The imminent dawn of SPRMs in obstetrics and gynecology","volume":"358","author":"Chabbert-Buffet","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.ajog.2017.12.206_bib8","article-title":"Mifepristone for uterine fibroids","volume":"8","author":"Tristan","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ajog.2017.12.206_bib9","article-title":"Selective progesterone receptor modulators (SPRMs) for uterine fibroids","volume":"4","author":"Murji","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ajog.2017.12.206_bib10","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.fertnstert.2006.11.094","article-title":"A\u00a0randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata","volume":"87","author":"Chwalisz","year":"2007","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ajog.2017.12.206_bib11","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1210\/jc.2008-1104","article-title":"Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy","volume":"93","author":"Wilkens","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ajog.2017.12.206_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/humupd\/dmu048","article-title":"Ovarian steroids, stem cells and uterine leiomyoma: therapeutic implications","volume":"21","author":"Moravek","year":"2015","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.ajog.2017.12.206_bib13","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cct.2017.02.002","article-title":"Rationale and design of ASTEROID 2, a randomized, placebo- and active comparator-controlled study to assess the efficacy and\u00a0safety of vilaprisan in patients with uterine\u00a0fibroids","volume":"55","author":"Seitz","year":"2017","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.ajog.2017.12.206_bib14","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/modpathol.2008.19","article-title":"The spectrum of endometrial pathology induced by progesterone receptor modulators","volume":"21","author":"Mutter","year":"2008","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ajog.2017.12.206_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/humupd\/dmm023","article-title":"Progesterone receptor modulators and the endometrium: changes and consequences","volume":"13","author":"Horne","year":"2007","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.ajog.2017.12.206_bib16","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1056\/NEJMoa1103182","article-title":"Ulipristal acetate versus placebo for fibroid treatment before surgery","volume":"366","author":"Donnez","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2017.12.206_bib17","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa1103180","article-title":"Ulipristal acetate versus leuprolide acetate for uterine fibroids","volume":"366","author":"Donnez","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2017.12.206_bib18","unstructured":"Fibristal (ulipristal acetate) [product monograph]. Markham, Ontario, Canada: Actavis Specialty Pharmaceuticals; Co;\u00a02016."},{"issue":"Suppl","key":"10.1016\/j.ajog.2017.12.206_bib19","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.1016\/j.fertnstert.2016.08.005","article-title":"First US-based phase 3 study of ulipristal acetate\u00a0(UPA) for symptomatic uterine fibroids (UF): results of VENUS-I","volume":"106","author":"Simon","year":"2016","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ajog.2017.12.206_bib20","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/PGP.0b013e318251035b","article-title":"Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate","volume":"31","author":"Williams","year":"2012","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.ajog.2017.12.206_bib21","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.fertnstert.2015.09.032","article-title":"Long-term medical management of uterine fibroids with ulipristal acetate","volume":"105","author":"Donnez","year":"2016","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ajog.2017.12.206_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.fertnstert.2014.02.008","article-title":"Long-term treatment of uterine fibroids with ulipristal acetate","volume":"101","author":"Donnez","year":"2014","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ajog.2017.12.206_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173523","article-title":"Safety after extended repeated use of ulipristal acetate for uterine fibroids","volume":"12","author":"Fauser","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ajog.2017.12.206_bib24","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.maturitas.2014.06.002","article-title":"EMAS position statement: management of uterine fibroids","volume":"79","author":"Perez-Lopez","year":"2014","journal-title":"Maturitas"},{"key":"10.1016\/j.ajog.2017.12.206_bib25","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/AOG.0b013e318183fbab","article-title":"ACOG practice bulletin. Alternatives to hysterectomy in the management of leiomyomas","volume":"112","year":"2008","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.12.206_bib26","unstructured":"Allergan. Press release: Allergan and Gedeon Richter announce positive phase III results for ulipristal acetate 5 and 10 mg in the treatment of uterine fibroids. Available at: https:\/\/www.allergan.com\/news\/news\/thomson-reuters\/allergan-and-gedeon-richter-announce-positive-phas. Accessed August 22, 2017."},{"key":"10.1016\/j.ajog.2017.12.206_bib27","unstructured":"Esmya (ulipristal acetate) [product information]. Melbourne, Australia: Vifor Pharma Pty Ltd; 2017."},{"key":"10.1016\/j.ajog.2017.12.206_bib28","unstructured":"Esmya (ulipristal acetate) [product information]. Budapest, Hungary: Gedeon Richter PLC;\u00a02016."},{"key":"10.1016\/j.ajog.2017.12.206_bib29","article-title":"Preoperative medical therapy before surgery for uterine fibroids","volume":"11","author":"Lethaby","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ajog.2017.12.206_bib30","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0015-0282(00)01767-2","article-title":"Goserelin acetate (Zoladex) plus endometrial ablation for dysfunctional uterine bleeding: a 3-year follow-up evaluation","volume":"75","author":"Donnez","year":"2001","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ajog.2017.12.206_bib31","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/j.fertnstert.2009.05.070","article-title":"GnRH analog treatment before hysteroscopic resection of submucous myomas: a prospective, randomized, multicenter study","volume":"94","author":"Muzii","year":"2010","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ajog.2017.12.206_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186158","article-title":"Pre-treatment with GnRHa or ulipristal acetate prior to laparoscopic and laparotomic myomectomy: a systematic review and meta-analysis","volume":"12","author":"de Milliano","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ajog.2017.12.206_bib33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.bpobgyn.2016.09.011","article-title":"Practical aspects of the two FIGO systems for management of abnormal uterine bleeding in the reproductive years","volume":"40","author":"Munro","year":"2017","journal-title":"Best\u00a0Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.ajog.2017.12.206_bib34","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jmig.2015.12.002","article-title":"Ulipristal acetate before high complexity hysteroscopic myomectomy: a retrospective comparative study","volume":"23","author":"Ferrero","year":"2016","journal-title":"J\u00a0Minim Invasive Gynecol"},{"key":"10.1016\/j.ajog.2017.12.206_bib35","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ejogrb.2016.01.014","article-title":"Hysteroscopic myomectomy outcomes after 3-month treatment with either ulipristal acetate or GnRH analogs: a retrospective comparative study","volume":"198","author":"Sancho","year":"2016","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.ajog.2017.12.206_bib36","article-title":"A\u00a0multicenter study evaluating the effect of ulipristal acetate during myomectomy","author":"Murji","year":"2017","journal-title":"J\u00a0Minim Invasive Gynecol"},{"key":"10.1016\/j.ajog.2017.12.206_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0130861","article-title":"Impact of preoperative anemia and blood transfusion on postoperative outcomes in gynecological surgery","volume":"10","author":"Richards","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ajog.2017.12.206_bib38","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ejogrb.2016.08.021","article-title":"Three-month treatment with ulipristal acetate\u00a0prior to laparoscopic myomectomy of large uterine myomas: a retrospective study","volume":"205","author":"Ferrero","year":"2016","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.ajog.2017.12.206_bib39","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.jmig.2017.02.025","article-title":"Does ulipristal acetate affect surgical experience at laparoscopic myomectomy?","volume":"24","author":"Luketic","year":"2017","journal-title":"J\u00a0Minim Invasive Gynecol"},{"key":"10.1016\/j.ajog.2017.12.206_bib40","first-page":"1439","article-title":"Myoma migration: an unexpected \"effect\" with ulipristal acetate treatment","volume":"20","author":"Willame","year":"2016","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.ajog.2017.12.206_bib41","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S1701-2163(15)30318-2","article-title":"The management of uterine fibroids in women with otherwise unexplained infertility","volume":"37","author":"Carranza-Mamane","year":"2015","journal-title":"J\u00a0Obstet Gynaecol Can"},{"key":"10.1016\/j.ajog.2017.12.206_bib42","article-title":"Endometrial changes in surgical specimens of perimenopausal patients treated with ulipristal acetate for uterine leiomyomas","author":"Nogales","year":"2017","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.ajog.2017.12.206_bib43","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S1701-2163(15)30939-7","article-title":"Abnormal uterine bleeding in pre-menopausal women","volume":"35","author":"Singh","year":"2013","journal-title":"J\u00a0Obstet Gynaecol Can"},{"key":"10.1016\/j.ajog.2017.12.206_bib44","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1097\/01.AOG.0000428646.67925.9a","article-title":"Management of acute abnormal uterine bleeding in nonpregnant reproductive-aged women. ACOG committee opinion no. 557","volume":"121","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.12.206_bib45","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1210\/jc.2006-2816","article-title":"Effects\u00a0of the progesterone receptor modulator VA2914 in a continuous low dose on\u00a0the hypothalamic-pituitary-ovarian axis and\u00a0endometrium in normal women: a\u00a0prospective, randomized, placebo-controlled trial","volume":"92","author":"Chabbert-Buffet","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ajog.2017.12.206_bib46","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejogrb.2016.11.003","article-title":"Real-world data of 1473 patients treated with ulipristal acetate for uterine fibroids: Premya study results","volume":"208","author":"Fernandez","year":"2017","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.ajog.2017.12.206_bib47","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/humrep\/det459","article-title":"Uterine artery embolization for severe symptomatic fibroids: effects on fertility and symptoms","volume":"29","author":"Torre","year":"2014","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ajog.2017.12.206_bib48","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.fertnstert.2014.07.1253","article-title":"First series of 18 pregnancies after ulipristal acetate treatment for uterine fibroids","volume":"102","author":"Luyckx","year":"2014","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ajog.2017.12.206_bib49","doi-asserted-by":"crossref","first-page":"756.e1","DOI":"10.1016\/j.ajog.2016.02.049","article-title":"Long-term nonsurgical control with ulipristal acetate of multiple uterine fibroids, enabling pregnancy","volume":"214","author":"Luyckx","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.12.206_bib50","first-page":"314587","article-title":"Successful pregnancy after treatment with ulipristal acetate for uterine fibroids","volume":"2014","author":"Monleon","year":"2014","journal-title":"Case Rep Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.12.206_bib51","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jogc.2015.11.004","article-title":"Spontaneous pregnancy following ulipristal acetate treatment in a woman with a symptomatic uterine fibroid","volume":"38","author":"Murad","year":"2016","journal-title":"J\u00a0Obstet Gynaecol Can"},{"key":"10.1016\/j.ajog.2017.12.206_bib52","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1097\/AOG.0b013e3182888478","article-title":"Surgical management of leiomyomas for fertility or uterine preservation","volume":"121","author":"Falcone","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.12.206_bib53","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/tog.12072","article-title":"Selective progesterone receptor modulators and their use within gynecology","volume":"16","author":"Murdoch","year":"2014","journal-title":"Obstetrician Gynaecologist"},{"key":"10.1016\/j.ajog.2017.12.206_bib54","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1093\/humrep\/dem177","article-title":"A\u00a0novel estrogen-free oral contraceptive pill for women: multicenter, double-blind, randomized controlled trial of mifepristone and progestogen-only pill (levonorgestrel)","volume":"22","author":"Lakha","year":"2007","journal-title":"Hum Reprod"}],"container-title":["American Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937817326972?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937817326972?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:33:55Z","timestamp":1762079635000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002937817326972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":54,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S0002937817326972"],"URL":"https:\/\/doi.org\/10.1016\/j.ajog.2017.12.206","relation":{},"ISSN":["0002-9378"],"issn-type":[{"value":"0002-9378","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The past, present, and future of selective progesterone receptor modulators in the management of uterine fibroids","name":"articletitle","label":"Article Title"},{"value":"American Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajog.2017.12.206","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}